Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy
Abstract The therapeutic effect of chemotherapeutics such as gemcitabine against pancreatic cancer is considerably attenuated by immune-suppressive tumor microenvironment. Improvement of chemotherapeutic efficacy by targeting tumor-associated macrophage and reprograming tumor microenvironment to enh...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-02-01
|
| Series: | Journal of Nanobiotechnology |
| Online Access: | https://doi.org/10.1186/s12951-022-01282-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559128549359616 |
|---|---|
| author | Meng Wang Qida Hu Junmin Huang Xinyu Zhao Shiyi Shao Fu Zhang Zhuo Yao Yuan Ping Tingbo Liang |
| author_facet | Meng Wang Qida Hu Junmin Huang Xinyu Zhao Shiyi Shao Fu Zhang Zhuo Yao Yuan Ping Tingbo Liang |
| author_sort | Meng Wang |
| collection | DOAJ |
| description | Abstract The therapeutic effect of chemotherapeutics such as gemcitabine against pancreatic cancer is considerably attenuated by immune-suppressive tumor microenvironment. Improvement of chemotherapeutic efficacy by targeting tumor-associated macrophage and reprograming tumor microenvironment to enhance their efficacy may become a promising strategy. To this end, we developed a biomimetic dual-targeting nanomedicine (PG@KMCM) where gemcitabine-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles are coated with a layer of bioengineered cancer cell membrane that stably expresses peptides targeting M2-like macrophages (M2pep) while reserving tumor-associated antigens (TAAs). The PG@KMCM nanomedicine enables the simultaneous targeted delivery of gemcitabine to pancreatic tumor sites and TAMs to potentiate its therapeutic effects. Furthermore, the combination of an immune checkpoint inhibitor (PD-L1 antibody) with PG@KMCM synergistically enhanced the anti-tumoral effect by reprogramming the immune-suppressive tumor microenvironment, including the elimination of PD-L1-positive macrophages and the downregulation of PD-L1 expression. Our study proved dual-targeting PG@KMCM nanomedicine in combination with PD-L1 immune checkpoint inhibitor therapy is able to effectively reprogram the tumor microenvironment and kill pancreatic cancer cells to enhance overall therapeutic potential. Graphical Abstract |
| format | Article |
| id | doaj-art-356d8690976344fb8ef033badcc775f3 |
| institution | Kabale University |
| issn | 1477-3155 |
| language | English |
| publishDate | 2022-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj-art-356d8690976344fb8ef033badcc775f32025-01-05T12:45:05ZengBMCJournal of Nanobiotechnology1477-31552022-02-0120111310.1186/s12951-022-01282-3Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapyMeng Wang0Qida Hu1Junmin Huang2Xinyu Zhao3Shiyi Shao4Fu Zhang5Zhuo Yao6Yuan Ping7Tingbo Liang8Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineCollege of Pharmaceutical Sciences, Zhejiang UniversityDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of MedicineAbstract The therapeutic effect of chemotherapeutics such as gemcitabine against pancreatic cancer is considerably attenuated by immune-suppressive tumor microenvironment. Improvement of chemotherapeutic efficacy by targeting tumor-associated macrophage and reprograming tumor microenvironment to enhance their efficacy may become a promising strategy. To this end, we developed a biomimetic dual-targeting nanomedicine (PG@KMCM) where gemcitabine-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles are coated with a layer of bioengineered cancer cell membrane that stably expresses peptides targeting M2-like macrophages (M2pep) while reserving tumor-associated antigens (TAAs). The PG@KMCM nanomedicine enables the simultaneous targeted delivery of gemcitabine to pancreatic tumor sites and TAMs to potentiate its therapeutic effects. Furthermore, the combination of an immune checkpoint inhibitor (PD-L1 antibody) with PG@KMCM synergistically enhanced the anti-tumoral effect by reprogramming the immune-suppressive tumor microenvironment, including the elimination of PD-L1-positive macrophages and the downregulation of PD-L1 expression. Our study proved dual-targeting PG@KMCM nanomedicine in combination with PD-L1 immune checkpoint inhibitor therapy is able to effectively reprogram the tumor microenvironment and kill pancreatic cancer cells to enhance overall therapeutic potential. Graphical Abstracthttps://doi.org/10.1186/s12951-022-01282-3 |
| spellingShingle | Meng Wang Qida Hu Junmin Huang Xinyu Zhao Shiyi Shao Fu Zhang Zhuo Yao Yuan Ping Tingbo Liang Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy Journal of Nanobiotechnology |
| title | Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| title_full | Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| title_fullStr | Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| title_full_unstemmed | Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| title_short | Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| title_sort | engineered a dual targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy |
| url | https://doi.org/10.1186/s12951-022-01282-3 |
| work_keys_str_mv | AT mengwang engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT qidahu engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT junminhuang engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT xinyuzhao engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT shiyishao engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT fuzhang engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT zhuoyao engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT yuanping engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy AT tingboliang engineeredadualtargetingbiomimeticnanomedicineforpancreaticcancerchemoimmunotherapy |